Markets

5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings

The drug/biotech industry has seen a mixed performance in the past six months. The Large Cap Pharmaceuticals sector (comprising some of the biggest drugmakers in the world) has gained 6.5% compared with the S&P 500's increase of 1.6%.

However, the riskier Medical-Biomedical and Genetics sector, which includes large as well as small biotech companies, has underperformed the S&P 500. The biotech industry has declined 10.3% against the S&P 500 increase of 1.6%, probably because of some pipeline setbacks faced by the industry.

Rising demand for new products, rampant innovation and product line extensions, strong clinical study results and frequent FDA approvals keep this sector on the growth track. Merger and acquisition (M&A) activity is gaining momentum with the new tax reform in place which is obviously a boon for any sector.

Meanwhile, government scrutiny of high drug prices, pricing and competitive pressure, slowdown in sales of some of the most high-profile older drugs and major pipeline setbacks act as deterrents.

Nonetheless, the drug/biotech industry is expected to recover from here. We believe that pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activity as well as appropriate utilization of cash should act in favor of the drug/biotech sector.

How to Pick Potential Q3 Winners?

There are a number of drug/biotech companies poised to surpass third-quarter estimates. However, given the large number of drug/biotech firms, the task of selecting stocks with possibilities to beat could appear quite daunting.

With the help of the Zacks Stock Screener , we have zeroed in on five drug/ biotech stocks that carry a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and have a positive Earnings ESP . It is a valuable tool for investors looking for stocks that are most likely to beat earnings estimates. Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .

5 Stocks Poised to Outperform

Allergan Plc.AGN has an Earnings ESP of +3.38% and a Zacks Rank #3. The Zacks Consensus Estimate for third-quarter 2018 is pegged at $4.01. The company has a trailing four-quarter average positive earnings surprise of 5.72%. The company is scheduled to report results on Oct 30, before market opens. You can see the complete list of today's Zacks #1 Rank stocks here.

Regeneron Pharmaceuticals Inc.REGN has an Earnings ESP of +4.65% and a Zacks Rank #3. The Zacks Consensus Estimate for third-quarter 2018 earnings is pegged at $5.21. The company has beaten earnings in the trailing four quarters, the average beat being 8.18%. The company is slated to release earnings on Nov 6, before market opens.

Amgen Inc.AMGN has an Earnings ESP of +3.54% and a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter 2018 is pegged at $3.42. The company has beaten earnings in three of the trailing four quarters, the average positive earnings surprise being 4.29%. The company is scheduled to release earnings on Oct 30 after market close.

Alnylam Pharmaceuticals Inc.ALNY has an Earnings ESP of +12.54% and a Zacks Rank #3. The Zacks Consensus Estimate for third-quarter 2018 bottom line is pegged at a loss of $1.80. Alnylam is expected to report earnings on Nov 6.

AMAG Pharmaceuticals, Inc.AMAG has an Earnings ESP of +13.76% and a Zacks Rank #3. The consensus mark for the third quarter stands at a loss of 67 cents. AMAG is slated to announce results on Nov 1, before market opens.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Allergan plc (AGN): Free Stock Analysis Report

AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN AMGN ALNY

Other Topics

Earnings

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More